Literature DB >> 24574498

Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.

Wensheng Wang1, Javier Rangel-Moreno, Teresa Owen, Jennifer Barnard, Sarah Nevarez, H Travis Ichikawa, Jennifer H Anolik.   

Abstract

Autoantibodies to dsDNA, produced by autoreactive plasma cells (PCs), are a hallmark of systemic lupus erythematosus and play a key role in disease pathogenesis. Recent data suggest that autoreactive PCs accumulate not only in lymphoid tissues, but also in the inflamed kidney in lupus nephritis. We hypothesized that the variable efficacy of anti-CD20 (rituximab)-mediated B cell depletion in systemic lupus erythematosus may be related to the absence of an effect on autoreactive PCs in the kidney. In this article, we report that an enrichment of autoreactive dsDNA Ab-secreting cells (ASCs) in the kidney of lupus-prone mice (up to 40% of the ASCs) coincided with a progressive increase in splenic germinal centers and PCs, and an increase in renal expression for PC survival factors (BAFF, a proliferation-inducing ligand, and IL-6) and PC attracting chemokines (CXCL12). Short-term treatment with anti-CD20 (4 wk) neither decreased anti-dsDNA nor IgG ASCs in different anatomical locations. However, long-term treatment (12 wk) significantly reduced both IgG- and dsDNA-specific ASCs. In addition, long-term treatment substantially decreased splenic germinal center and PC generation, and unexpectedly reduced the expression for PC survival factors in the kidney. These results suggest that prolonged B cell depletion may alter the PC survival niche in the kidney, regulating the accumulation and maintenance of autoreactive PCs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574498      PMCID: PMC3965596          DOI: 10.4049/jimmunol.1302003

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

2.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 3.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

4.  Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice.

Authors:  Stéphanie Lacotte; Hélène Dumortier; Marion Décossas; Jean-Paul Briand; Sylviane Muller
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

5.  High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice.

Authors:  Charlotte Starke; Silke Frey; Ute Wellmann; Vilma Urbonaviciute; Martin Herrmann; Kerstin Amann; Georg Schett; Thomas Winkler; Reinhard E Voll
Journal:  Eur J Immunol       Date:  2011-06-06       Impact factor: 5.532

6.  Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.

Authors:  Chaim O Jacob; Shunhua Guo; Noam Jacob; Rahul D Pawar; Chaim Putterman; William J Quinn; Michael P Cancro; Thi-Sau Migone; William Stohl
Journal:  Arthritis Rheum       Date:  2012-05

7.  A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Meera Ramanujam; Ranjit Sahu; Weijia Zhang; Yezou Sun; Erwin P Bottinger; Lionel Ivashkiv; Matthias Kretzler; Anne Davidson
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

8.  Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Authors:  H Travis Ichikawa; Thomas Conley; Tony Muchamuel; Jing Jiang; Susan Lee; Teresa Owen; Jennifer Barnard; Sarah Nevarez; Bruce I Goldman; Christopher J Kirk; R John Looney; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2012-02

9.  Local renal autoantibody production in lupus nephritis.

Authors:  Marion Espeli; Susanne Bökers; Giovanna Giannico; Harriet A Dickinson; Victoria Bardsley; Agnes B Fogo; Kenneth G C Smith
Journal:  J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 10.121

10.  Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.

Authors:  Meera Ramanujam; Ramalingam Bethunaickan; Weiqing Huang; Haiou Tao; Michael P Madaio; Anne Davidson
Journal:  Arthritis Rheum       Date:  2010-05
View more
  17 in total

1.  Identification of a new subset of lymph node stromal cells involved in regulating plasma cell homeostasis.

Authors:  Hsin-Ying Huang; Ana Rivas-Caicedo; François Renevey; Hélène Cannelle; Elisa Peranzoni; Leonardo Scarpellino; Debbie L Hardie; Arnaud Pommier; Karin Schaeuble; Stéphanie Favre; Tobias K Vogt; Fernando Arenzana-Seisdedos; Pascal Schneider; Christopher D Buckley; Emmanuel Donnadieu; Sanjiv A Luther
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-02       Impact factor: 11.205

2.  Small Molecule Inhibition of Rab7 Impairs B Cell Class Switching and Plasma Cell Survival To Dampen the Autoantibody Response in Murine Lupus.

Authors:  Tonika Lam; Dennis V Kulp; Rui Wang; Zheng Lou; Julia Taylor; Carlos E Rivera; Hui Yan; Qi Zhang; Zhonghua Wang; Hong Zan; Dmitri N Ivanov; Guangming Zhong; Paolo Casali; Zhenming Xu
Journal:  J Immunol       Date:  2016-10-14       Impact factor: 5.422

3.  Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.

Authors:  Liudmila Kulik; Jennifer Laskowski; Brandon Renner; Rachel Woolaver; Lian Zhang; Taras Lyubchenko; Zhiying You; Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2019-11-15       Impact factor: 5.422

Review 4.  B cell targeted therapies in autoimmune disease.

Authors:  Jennifer L Barnas; Richard John Looney; Jennifer H Anolik
Journal:  Curr Opin Immunol       Date:  2019-11-14       Impact factor: 7.486

Review 5.  New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome.

Authors:  Anna K Bird; Nida Meednu; Jennifer H Anolik
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

Review 6.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

7.  Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Authors:  Ding Chen; Monica Blazek; Sara Ireland; Sterling Ortega; Xiangmei Kong; Anouk Meeuwissen; Ann Stowe; Laura Carter; Yue Wang; Ronald Herbst; Nancy L Monson
Journal:  J Immunol       Date:  2014-10-03       Impact factor: 5.422

8.  Small Molecule Inhibitors of Nuclear Export and the Amelioration of Lupus by Modulation of Plasma Cell Generation and Survival.

Authors:  Javier Rangel-Moreno; Maria de la Luz Garcia-Hernandez; Teresa Owen; Jennifer Barnard; Enrique Becerril-Villanueva; Trinayan Kashyap; Christian Argueta; Armando Gamboa-Dominguez; Sharon Tamir; Yosef Landesman; Bruce I Goldman; Christopher T Ritchlin; Jennifer H Anolik
Journal:  Arthritis Rheumatol       Date:  2022-06-28       Impact factor: 15.483

9.  Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.

Authors:  Adriano Taddeo; Laleh Khodadadi; Caroline Voigt; Imtiaz M Mumtaz; Qingyu Cheng; Katrin Moser; Tobias Alexander; Rudolf A Manz; Andreas Radbruch; Falk Hiepe; Bimba F Hoyer
Journal:  Arthritis Res Ther       Date:  2015-03-02       Impact factor: 5.156

Review 10.  The Role of CXCL12 in Kidney Diseases: A Friend or Foe?

Authors:  Anni Song; Anni Jiang; Wei Xiong; Chun Zhang
Journal:  Kidney Dis (Basel)       Date:  2021-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.